timothy sykes logo

Stock News

Compass Pathways Shares Surge After Major Depression Therapy Breakthrough

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 2/18/2026, 11:33 am ET 2/18/2026, 11:33 am ET | 5 min 5 min read
Compass Pathways Shares Surge After Major Depression Therapy Breakthrough Thumbnail

COMPASS Pathways Plc stocks have been trading up by 10.22 percent amid positive developments and potential market expansion.

Candlestick Chart

Live Update At 11:32:28 EST: On Wednesday, February 18, 2026 COMPASS Pathways Plc stock [NASDAQ: CMPS] is trending up by 10.22%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The recent stock antics of Compass Pathways tell a story of ups and downs. Opening at a humble $7.83 on Feb 17, it shot up to $8.75 before closing at $8.41 on Feb 18. This translates to a 10% gain in just one day, a signal of bullish undertones. Such enthusiasm largely ties back to their announcement of successful phase 3 trials, marking a major stride in treating depression more effectively.

The company’s past, captured by financial statements, shows continuous losses, with a recent $137.71M net loss barely overshadowed by bright prospects from their clinical victories. A chased market entry spotlights Compass’s patented psilocybin therapy, suggesting a return to revenue growth after past droughts. Also finding its way to investors’ tables was news on a share dibble, fetching a hefty $150M yet potentially watering down current stakes. This tit-for-tat, prominently featured in their balance number, outlines a calculated risk move of raising cash for brighter horizons.

Financial ratios reflect Compass’s situation well. Speculated BVPS at $4 shows there’s a tang of tangible value amidst theoretical musings. Meanwhile, a mounting debt furthers a tale of caution as liabilities gallop past equity values. Investors might just wait for clearer clouds on costs and margins amid these developments.

Riding the Psychedelic Wave: Market Impact

The Phases 3 trials were no small feat. Such milestones are rare for seen-up-as-eye spots like Compass, and success with rapid, enduring results clangs big bells across the mental health space. Aided by gains from their use, both FDA and UK regulatory bodies earned Breakthrough Designation and ILAP, assisting in development ease. This indeed raises the stakes for chronic non-responders of standard treatments who make perfect candidates for new relief brinks.

However, Compass’s journey isn’t without bumps. A $150M public offering now speeds towards followers, ready to bank on investments for potential outbursts in the treatment realm. While existing travelers might sense thinning waters from additional shares, possible exchanges exceed hurdles and bolster overall terms.

With COMP360 strengthening CMPS’s play, future inputs may flag expanded core fits. A rise from $16 to $21 in stock price hints at unbridled forecasts and speaks volumes to investor camaraderie amid temporary turbulence. Bearish blushes over high studies simmer still on solid sentiment – a lively duo in competitive angst.

More Breaking News

Conclusion

Golden prospects loom large above CMPS, refusing to rest despite economical ebbs. To the commonwealth hipster, a narrative springs out of them finding solace in improved medicamentality for stubborn shadows. A seasoned thread yearns to bolster society in measurable means and possibly bring light to a struggling market. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This sentiment resonates with traders seeking sustainable gains. Such an outcome is always well received as individuals vie to dance among an everdrifting arena, unyield baselines, and extend touches of colored vibrancy. While commercial tides might chisel away the chaotic buildup, Compass’s offers great expectations for those riding the human wave.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”